Review Of Pfizer’s Maraviroc Will Reflect CCR5 Antagonist Class Safety Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Antiviral Drugs Advisory Committee will also assess whether existing data supports accelerated approval for the first-in-class HIV therapy.
You may also be interested in...
Pfizer’s Maraviroc Deemed “Approvable” By FDA
Pfizer says it is working with FDA to finalize product labeling for the HIV treatment as soon as possible.
Pfizer’s Maraviroc Deemed “Approvable” By FDA
Pfizer says it is working with FDA to finalize product labeling for the HIV treatment as soon as possible.
Pfizer’s Maraviroc Unanimously Recommended For Accelerated Approval
However, members of FDA’s Antiviral Drugs Advisory Committee voice numerous concerns, recommending additional data or analysis for full approval of the CCR5 antagonist.